Full text is available at the source.
Impact of the initial decline in estimated glomerular filtration rate on the risk of new‐onset atrial fibrillation and adverse cardiovascular and renal events in patients with type 2 diabetes treated with sodium‐glucose co‐transporter‐2 inhibitors
Early kidney function drop linked to risk of irregular heartbeat and heart and kidney problems in type 2 diabetes patients taking SGLT2 inhibitors
AI simplified
Abstract
SGLT2i treatment was associated with an initial eGFR decline of 3.5% ± 14.0% after a median treatment period of 10 weeks.
- 37.1% of patients experienced no eGFR decline following treatment.
- 30.5% experienced a decline of 0%-10%, while 30.5% declined by 10%-20%, 20.2% by 20%-30%, and 3.7% by more than 30%.
- The mean eGFR stabilized after 6 months across all decline categories, even for those with declines greater than 30%.
- An eGFR decline of more than 30% was linked to a higher risk of new-onset atrial fibrillation, major adverse cardiovascular events, and composite renal outcomes.
- Independent factors associated with a decline of more than 30% included older age, female sex, higher HbA1c levels, and a lower body mass index.
AI simplified